FDA Warns Against Marijuana Products’ Cancer-Fighting Claims

Federal heath regulators have sent a warning letter to several licensed marijuana manufacturers, ordering them to stop making claims that their products can cure or treat cancer, which has never been proven. 

Four companies that sell marijuana plant extracts received the FDA warning notice, over false claims that their products help diagnose, treat, or cure cancer. The unsupported statements may lead to cancer patients not seeking proper treatments, worsening their condition, the agency warns.

At issue are claims that products with the marijuana plant extract, cannabidiol (CBD), have cancer curing benefits. Cannabidiol is a component of the marijuana plant that is extracted and sold in many different forms such as oil drops, capsules, syrups, teas, and topical lotions and creams. Many consumers believe that the oil provides a wide variety of medical benefits, however, the FDA states that no scientific or medical evidence has supported these claims.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

The FDA issued the warning letters after discovering the four companies were advertising that cannabidiol products could prevent, reverse, or cure cancer, or kill and inhibit cancer cells or tumors, along with various other anti-cancer claims.

The warning letters also claim that some of the products were advertised as an alternative or additional treatment for Alzheimer’s and other serious diseases.

The FDA sets advertising guidelines for companies to prevent consumers from receiving false or misleading information. The guidelines are meant to protect consumer health, so that patients with mild to severe diseases do not seek the wrong treatment and delay proper treatment, which could result in a worsened or fatal condition.

The FDA approval process is also meant to help determine proper dosage, risks the products could pose if used with additional medications, and whether any dangerous side effects need to be disclosed.

“When people are allowed to illegally market agents that deliver no established benefit they may steer patients away from products that have proven, anti-tumor effects that could extend lives, ” FDA Commissioner, Scott Gottlieb, stated in the press release.

Gottlieb said the agency is aware of marijuana extracts health claims, however there is an official process that must be followed before companies can make medical benefit claims.

The FDA sent the warning letters to Greenroads Health, Natural Alchemist, That’s Natural! Marketing and Consulting, and Stanley Brothers Social Enterprise LLC. Combined, the companies were accused of making more than 25 unsubstantiated claims of medical benefits related to the use of cannabidiol.

The companies must respond to the warning letter with how the violations will be corrected in a timely fashion. Failure to comply may result in legal action by the FDA, including seizure and injunction.

The latest action builds on at least 90 warning letters issued to companies by the FDA in the last ten years, including more than a dozen this year, who all have made deceptive or fraudulent marketing claims of benefits to cure of prevent cancer by way of website, social media or in store advertising.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

AT&T Data Breach Lawsuits Seek Damages for 70M Customers Whose Information Was Released
AT&T Data Breach Lawsuits Seek Damages for 70M Customers Whose Information Was Released (Posted yesterday)

AT&T faces a growing number of data breach class action lawsuits, which plaintiffs say should be consolidated before one federal judge for coordinated pretrial proceedings.

Fairness of Philips CPAP Recall Settlement Being Evaluated By MDL Judge
Fairness of Philips CPAP Recall Settlement Being Evaluated By MDL Judge (Posted 2 days ago)

A federal judge has held a fairness hearing for a proposed Philips CPAP class action lawsuit settlement, which seeks to resolve claims that consumers suffered economic damages due to the massive recall over toxic sound abatement foam.